Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

PHILIP J. MEASE, NATHAN WEI, EDWARD J. FUDMAN, ALAN J. KIVITZ, JOY SCHECHTMAN, ROBERT G. TRAPP, KATHRYN F. HOBBS, MARIA GREENWALD, ANTONY HOU, STEPHEN A. BOOKBINDER, GALEN E. GRAHAM, CRAIG W. WIESENHUTTER, LARRY WILLIS, ERIC M. RUDERMAN, JOSEPH Z. FORSTOT, MICHAEL J. MARICIC, KATHRYN H. DAO, CHARLES H. PRITCHARD, DARRELL N. FISKE, FRANCIS X. BURCH, H. MALIN PRUPAS, PERVIN ANKLESARIA and ALISON E. HEALD
The Journal of Rheumatology April 2010, 37 (4) 692-703; DOI: https://doi.org/10.3899/jrheum.090817
PHILIP J. MEASE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pmease@nwlink.com
NATHAN WEI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDWARD J. FUDMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALAN J. KIVITZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOY SCHECHTMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT G. TRAPP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATHRYN F. HOBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA GREENWALD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTONY HOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHEN A. BOOKBINDER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GALEN E. GRAHAM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CRAIG W. WIESENHUTTER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LARRY WILLIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERIC M. RUDERMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEPH Z. FORSTOT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL J. MARICIC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATHRYN H. DAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHARLES H. PRITCHARD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DARRELL N. FISKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCIS X. BURCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. MALIN PRUPAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PERVIN ANKLESARIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALISON E. HEALD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.

Methods. In this phase 1/2 randomized study, adults with persistent moderate or severe inflammation in a target joint, being treated with or without systemic anti-TNF therapy, received a single IA injection of either rAAV2-TNFR:Fc (1 × 1011, 1 × 1012, or 1 × 1013 DNase-resistant particles/ml joint volume) or placebo, followed by open-label rAAV2-TNFR:Fc 12–30 weeks later, depending on when the target joint met predetermined criteria for reinjection.

Results. 127 subjects received the first injection of blinded study drug; 95 subjects received open-label rAAV2-TNFR:Fc. Administration site reactions, consisting of transient mild to moderate increases in tenderness and swelling of the injected joint, occurred after 23/191 (12%) rAAV2-TNFR:Fc injections and were dose-dependent. Rates of other adverse events were not dose-dependent. Notable serious adverse events (SAE) included culture-negative septic arthritis in a subject receiving leflunomide and fatal disseminated histoplasmosis considered unrelated to rAAV2-TNFR:Fc in a subject receiving adalimumab. In the phase 2 portion of the study, a 30% decrease in target joint global visual analog scale was observed in 21/50 (42%) rAAV2-TNFR:Fc subjects and 3/16 (19%) placebo subjects 12 weeks after first injection (p = 0.14).

Conclusion. IA rAAV2-TNFR:Fc resulted in administration site reactions after 12% of injections. A fatal SAE, disseminated histoplasmosis, was considered not related to study agent. Patient-reported outcome measures of clinical response showed greater improvement in treated patients than placebo patients.

  • TUMOR NECROSIS FACTOR INHIBITORS
  • RHEUMATOID ARTHRITIS
  • PSORIATIC ARTHRITIS
  • BIOLOGICAL THERAPY
  • CLINICAL TRIALS

Footnotes

  • Supported by Targeted Genetics Corporation, Seattle, WA.

    • Accepted for publication November 9, 2009.
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 4
1 Apr 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study
PHILIP J. MEASE, NATHAN WEI, EDWARD J. FUDMAN, ALAN J. KIVITZ, JOY SCHECHTMAN, ROBERT G. TRAPP, KATHRYN F. HOBBS, MARIA GREENWALD, ANTONY HOU, STEPHEN A. BOOKBINDER, GALEN E. GRAHAM, CRAIG W. WIESENHUTTER, LARRY WILLIS, ERIC M. RUDERMAN, JOSEPH Z. FORSTOT, MICHAEL J. MARICIC, KATHRYN H. DAO, CHARLES H. PRITCHARD, DARRELL N. FISKE, FRANCIS X. BURCH, H. MALIN PRUPAS, PERVIN ANKLESARIA, ALISON E. HEALD
The Journal of Rheumatology Apr 2010, 37 (4) 692-703; DOI: 10.3899/jrheum.090817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study
PHILIP J. MEASE, NATHAN WEI, EDWARD J. FUDMAN, ALAN J. KIVITZ, JOY SCHECHTMAN, ROBERT G. TRAPP, KATHRYN F. HOBBS, MARIA GREENWALD, ANTONY HOU, STEPHEN A. BOOKBINDER, GALEN E. GRAHAM, CRAIG W. WIESENHUTTER, LARRY WILLIS, ERIC M. RUDERMAN, JOSEPH Z. FORSTOT, MICHAEL J. MARICIC, KATHRYN H. DAO, CHARLES H. PRITCHARD, DARRELL N. FISKE, FRANCIS X. BURCH, H. MALIN PRUPAS, PERVIN ANKLESARIA, ALISON E. HEALD
The Journal of Rheumatology Apr 2010, 37 (4) 692-703; DOI: 10.3899/jrheum.090817
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
  • Clustering Patients With Gout Based on Comorbidities and Biomarkers: A Cross-Sectional Study
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire